Jesús Berdeja, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the updated results from KarMMa (NCT03361748), a study aiming to evaluate the efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in relapsed/refractory (R/R) multiple myeloma. With a median age of 69, most myeloma patients are considered elderly, so studying the impact of age is important. In the KarMMa cohort, the response to ide-cel treatment was not impacted by age, with the results seen in those over 65 and over 70 similar to those seen in younger patients. No increase in toxicities was found, suggesting that age should not be the deciding factor when choosing ide-cel treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.